Oncology

After securing its Nasdaq spot, TuHURA Biosciences shifts focus to its promising immuno-oncology pipeline, aiming to tackle cancer treatment resistance.

MedX Health Corp. lands a crucial $2.7M in initial funding, aiming for $5M to expand its skin-screening tech into occupational health and manage debt.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

Michigan's largest independent oncology practice adds urology, promising patients more coordinated, lower-cost care outside of traditional hospital systems.

A key partnership ensures the supply of a breakthrough therapy for FOP, a devastating condition where muscle turns to bone, highlighting a new era in drug production.

Sensus Healthcare's new Sensus Link software aims to upgrade existing skin cancer treatment systems, signaling a major strategic shift to the cloud.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

With stellar clinical data and a full war chest, Terns is hitting the road to convince investors its leukemia drug, TERN-701, is a true disruptor.

Following a record year, Fingerpaint Group elevates veteran insiders to top roles, proving its culture-first succession strategy is a blueprint for success.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

A landmark partnership aims to bring precision cancer therapy, or Theranostics, to millions in underserved nations, backed by a major WHO resolution.

By fitting into existing hospital rooms, Mevion's newly CE-Marked proton therapy system aims to slash costs and expand access to advanced cancer treatment.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.

The healthcare specialist reported a staggering 2025 net loss due to a write-down, but projects 30% revenue growth fueled by new contracts.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

A planned reverse merger for promising vaccine developer SVF Vaccines has collapsed after Nasdaq rejected the deal, leaving its lead investor scrambling.